期刊文献+

异烟肼缓释固体分散体的制备及其体外评价 被引量:3

Preparation and in Vitro Release Evaluation of Isoniazid Solid Dispersion
原文传递
导出
摘要 目的制备异烟肼缓释固体分散体,考察其分散状态和体外溶出速率。方法以水不溶性聚合物乙基纤维素为载体,用溶剂法制备异烟肼缓释固体分散体。采用X射线衍射法、差示扫描量热法和红外光谱法鉴别药物在固体分散体中的存在状态,并对其体外释放情况进行研究。结果 X射线衍射法表明异烟肼在固体分散体中有一部分是以分子状态分散,而另一部分可能以微晶体状态分散;差示扫描量热法表明所制备的缓释固体分散体中不存在药物结晶;红外光谱法结果表明异烟肼与乙基纤维素未发生化学反应;溶出度试验结果表明其具有良好的缓释效果。结论采用溶剂法制备的异烟肼缓释固体分散体可以使药物达到高度分散状态,制备的异烟肼缓释固体分散体具有较好的缓释效果。 OBJECTIVE To prepare and identify sustained-release of isoniazid solid dispersion(SD) and evaluate its in vitro dissolution profile.METHODS The isoniazid SD was prepared by using water-insoluble polymer ethyl cellulose(EC) as carrier.X-ray diffraction,differential scanning calotimetery(DSC) and infrared spectroscopy(IR) were used to evaluate the dispersing state of isoniazid in SD and in vitro dissolution of isoniazid SD was performed.RESULTS X-ray diffraction analysis showed that the isoniazid was existed in both molecuar and micro-crystal form.DSC curve indicated that there was no isoniazid crystal in the SD.IR spectrum showed that there was no chemical reaction of isoniazid with the EC.The test for dissolution rate showed a better releasing in SD.CONCLUSION The SD can disperse the isoniazid to get sustained-release effect.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2011年第2期142-145,共4页 Chinese Journal of Modern Applied Pharmacy
基金 “十一五”科技重大专项(2008ZX10003-016)
关键词 异烟肼 乙基纤维素 固体分散体 X射线衍射法 差示扫描量热法 红外光谱法 isoniazid ethyl cellulose solid dispersion X-ray diffraction differential scanning calorimetry infrared spectroscopy
  • 相关文献

参考文献2

二级参考文献8

共引文献10

同被引文献29

  • 1CARDENAS A,GINES P,MAROTTA P, et al. Tolvaptan, anoral vasopressin antagonist,in the treatment of hyponatremiain cirrhosis [J]. J Hepatol, 2012,56(3): 571-578.
  • 2SCHRIER R W,GROSS P, GHEORGHIADE M, et al.Tolvaptan, a selective oral vasopressin V2-receptorantagonist,for hyponatremia [J]. New Eng J Med, 2006,355(20):2099-2112.
  • 3SHINSUKE N,KAI S,TADASHI M. Pharmaceutical solidpreparation and production method thereof: China,200880021079 [P]. 2010-03-31.
  • 4SHINSUKE N, HIROBUMI D,MUTSUMI I. Solidpreparation composition: Japan, 11-21241 [P]. 1999-01-26.
  • 5YASUHIRO T, KAORU A, YASUAKI M,et al. Method ofmanufacturing benzoazepin compound or its salt: China,200680032190 [P]. 2011-09-14.
  • 6Kang S S. Saponins from the roots of PuLsatilla koreana [J]. Arch Pharm Res, 1989, 12(1): 42-47.
  • 7Mi K S, Kyung H J, Sang W H, et al. SB365, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/mTOR signaling pathway [J]. Food Chem, 2013, 136(1): 26-33.
  • 8Sang W H, Kyung H J, Hee S L, et al. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway [J]. Cancer Sei, 2012, 103(11): 1929-1937.
  • 9Yong K, Scong C B, Ji H L, et al. Pulsatilla saponin D: the antitumor principle from Pulsatilla koreana [J]. Arch Pharm Res, 2004, 27(9): 915-918.
  • 10Bang S C, Lee J H, Song G Y, et al. Antitumor activity of Pulsatilla koreana saponins and their structure-activity relationship [J]. Chem Pharm Bull, 2005, 53(11): 1451-1454.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部